Experts Defend UK Agency Over Rapid Authorization Of COVID-19 Vaccine

EMA Explains Its ‘Softly Softly’ Approach

As arguments rage over whether the UK regulator has rushed its assessment of the Pfizer/BioNTech vaccine, the European Medicines Agency explains why its conditional marketing authorization approach is taking a little longer.

Pfizer Inc. and BioNTech, are pharmaceutical companys, working together on the development of a vaccine against the coronavirus. Logos are printed on white paper background
The first batch of the Pfizer/BioNTech COVID-19 vaccine is on its way to the UK • Source: Shutterstock

It is truly impressive to see a new coronavirus vaccine designed, developed, manufactured, authorized and prepared for distribution in a matter of months rather than the years this process would normally take.

The warm glow of this landmark achievement has been somewhat tarnished by arguments over the rigor of the UK regulator’s...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United Kingdom

More from Europe